Feb 12, 2018
|
Ardelyx Announces Departure of Chief Scientific Officer
|
Feb 8, 2018
|
Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference
|
Jan 3, 2018
|
Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference
|
Jan 3, 2018
|
Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
|
Dec 11, 2017
|
Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
|
Nov 28, 2017
|
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
|
Nov 21, 2017
|
Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
|
Nov 7, 2017
|
Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
|
Oct 16, 2017
|
Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
|
Oct 11, 2017
|
Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
|